C. J. SNEERINGER ET AL: "Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 107, no. 49, 7 December 2010 (2010-12-07), pages 20980-20985, XP55075961, ISSN: 0027-8424, DOI: 10.1073/pnas.1012525107 (B1)

YAP D.B. ET AL.: 'Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3-K27 trimethylation.' BLOOD vol. 117, no. 8, 29 December 2010, pages 2451 - 2459, XP055075957 (B1)

MIRANDA, TINA B. ET AL.: 'DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation.' MOL CANCER THER. vol. 8, no. 6, 09 June 2009, pages 1579 - 1588, XP055049435 (B1)

QI WEI ET AL: "Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 26 DEC 2012, vol. 109, no. 52, 26 December 2012 (2012-12-26), pages 21360-21365, XP002720302, ISSN: 1091-6490 (B1)

RICHON VICTORIA M ET AL: "Lymphoma-Associated Mutations of EZH2 Result In a Change-of-Function", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 116, no. 21, 1 November 2010 (2010-11-01), page 312, XP009176070, ISSN: 0006-4971 (B1)

RYAN D MORIN ET AL: "Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin", NATURE GENETICS, vol. 42, no. 2, 1 February 2010 (2010-02-01), pages 181-185, XP055101779, ISSN: 1061-4036, DOI: 10.1038/ng.518 (B1)

SHIVANI GARAPATY-RAO ET AL: "Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth", CHEMISTRY & BIOLOGY, vol. 20, no. 11, 1 November 2013 (2013-11-01), pages 1329-1339, XP055101733, ISSN: 1074-5521, DOI: 10.1016/j.chembiol.2013.09.013 (B1)

T. B. MIRANDA ET AL: "DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation", MOLECULAR CANCER THERAPEUTICS, vol. 8, no. 6, 1 June 2009 (2009-06-01), pages 1579-1588, XP055049435, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-09-0013 (B1)

TIM J WIGLE ET AL: "The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 585, no. 19, 9 August 2011 (2011-08-09), pages 3011-3014, XP028300045, ISSN: 0014-5793, DOI: 10.1016/J.FEBSLET.2011.08.018 [retrieved on 2011-08-17] (B1)

US-A1- 2005 266 473 (B1)

US-A1- 2008 222 741 (B1)

US-A1- 2009 012 031 (B1)

WO-A1-2011/140324 (B1)

WO-A2-2009/124137 (B1)

D. B. YAP ET AL: "Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation", BLOOD, vol. 117, no. 8, 29 December 2010 (2010-12-29), pages 2451-2459, XP055075957, ISSN: 0006-4971, DOI: 10.1182/blood-2010-11-321208 (B1)